跳至主要内容
临床试验/NCT01477424
NCT01477424已完成1 期

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Warfarin in Healthy Male and Female Adults

Vifor Pharma1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2011年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
45
试验地点
1
主要终点
Area Under the Curve from time zero to infinite (AUC0-infinity)

研究概览

简要总结

The purpose of this study is to determine if Warfarin is affected by PA21.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Basic Science
盲法
None

入排标准

年龄范围
20 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy volunteers
  • Written informed consent

排除标准

  • No significant medical conditions
  • Pregnancy

研究组 & 干预措施

PA21 and Warfarin with food

Experimental

The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day

干预措施: PA21 (Drug)

PA21 and Warfarin with food

Experimental

The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Warfarin will be 10 mg/day

干预措施: Warfarin (Drug)

No PA21; Warfarin with food

Experimental

The maximum dosage of Warfarin will be 10 mg/day

干预措施: Warfarin (Drug)

PA21 with food and Warfarin 2hrs later

Experimental

The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day

干预措施: PA21 (Drug)

PA21 with food and Warfarin 2hrs later

Experimental

The maximum dose of PA21 will be 15 g/day. The maximum dose of Warfarin will be 10 mg/day

干预措施: Warfarin (Drug)

结局指标

主要结局

Area Under the Curve from time zero to infinite (AUC0-infinity)

时间窗: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post Warfarin dose on Days 0, 11, 22

Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time

Maximum observed plasma concentration (Cmax)

时间窗: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120 and 168 hours post Warfarin dose on days 0, 11, 22

Area Under the Curve from time zero to 24 hours (AUC0-24)

时间窗: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96, 120, 144 and 168 hours post Warfarin dose on Days 0, 11, 22

Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours

次要结局

未报告次要终点

研究者

发起方
Vifor Pharma
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验